EZH2 in Bladder Cancer, a Promising Therapeutic Target

International Journal of Molecular Sciences

Mónica Martínez-Fernández¹  Carolina Rubio¹  Cristina Segovia¹  Fernando F. López-Calderón¹  Marta Dueñas¹  Jesús M. Paramio¹ 

[1] Molecular Oncology Unit, CIEMAT (Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas), Avenida Complutense nº40. 28040 Madrid, Spain;

关键词: bladder cancer;    Polycomb;    EZH2;    miRNA;    lncRNA;   

DOI  :  10.3390/ijms161126000

来源: mdpi

【 摘 要 】

Bladder Cancer (BC) represents a current clinical and social challenge. The recent studies aimed to describe the genomic landscape of BC have underscored the relevance of epigenetic alterations in the pathogenesis of these tumors. Among the epigenetic alterations, histone modifications occupied a central role not only in cancer, but also in normal organism homeostasis and development. EZH2 (Enhancer of Zeste Homolog 2) belongs to the Polycomb repressive complex 2 as its catalytic subunit, which through the trimethylation of H3 (Histone 3) on K27 (Lysine 27), produces gene silencing. EZH2 is frequently overexpressed in multiple tumor types, including BC, and plays multiple roles besides the well-recognized histone mark generation. In this review, we summarize the present knowledge on the oncogenic roles of EZH2 and its potential use as a therapeutic target, with special emphasis on BC pathogenesis and management.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.